Vir and GlaxoSmithKline begin pivotal study of Covid-19 antibody drug
MATT WINKELMEYER/GETTY IMAGES
The companies lag other drug makers developing antibody treatments but they expect their treatment could have certain advantages.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario